Comment on

• Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

  Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Sekulic A, et al. N Engl J Med. 2012 Jun 7;366(23):2171-9. doi: 10.1056/NEJMoa1113713. N Engl J Med. 2012. PMID: 22670903 Free PMC article. Clinical Trial.
• Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.

  Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH Jr. Tang JY, et al. N Engl J Med. 2012 Jun 7;366(23):2180-8. doi: 10.1056/NEJMoa1113538. N Engl J Med. 2012. PMID: 22670904 Free PMC article. Clinical Trial.
• Oral hedgehog-pathway inhibitors for basal-cell carcinoma.

  Lear JT. Lear JT. N Engl J Med. 2012 Jun 7;366(23):2225-6. doi: 10.1056/NEJMe1202170. N Engl J Med. 2012. PMID: 22670909 No abstract available.